Drug intelligence / Profile preview

SiB-2111

Development stage: Preclinical
Lead developer: Signadori Bio
Modality: Immune Effector Cells → Other Cell Types → Cell Therapies

Overview

SiB-2111 is an experimental in vivo monocyte immunotherapy being developed by Signadori Bio for the treatment of solid tumors. It is part of a platform designed to engineer monocytes directly within the patient's body to enhance anti-tumor immune responses. SiB-2111 specifically targets the cyclin-dependent kinase inhibitor 1 (p21, encoded by the CDKN1A gene) and an additional undisclosed molecular target (Target 2). By modulating these pathways, the therapy aims to reprogram the myeloid compartment of the tumor microenvironment from a pro-tumorigenic to an anti-tumorigenic state. As of early 2024, SiB-2111 is in the discovery phase of development.

Beyond the preview

Go deeper on SiB-2111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SiB-2111.

Explore the full profile